AMAL aims to tackle the obstacles for effective anti-cancer therapy by stimulating a patient’s immune system in a unique way.
KISIMA®, our unique proprietary protein-based immunisation platform is self-adjuvanting and delivers several antigens in one single vaccine.
We focus on the development of viable effective cancer therapies. Our most advanced asset is ATP128, a therapeutic vaccine for the treatment of metastatic colorectal cancers.
Our strategy is to develop KISIMA® and its current indications in oncology through to phase II, in-house or through strategic partnerships.
European Life Sciences CEO Forum 2019
25 & 26 February 2019 / Zurich / Switzerland
Madiha Derouazi and Laurence de Schoulepnikoff attending
BIO International Convention 2019
3 to 6 June 2019 / Philadelphia / USA
Madiha Derouazi attending
AACR Annual Meeting 2019
March 29 – Apr 3, 2019 / Atlanta / USA
Jean-François Mayol attending
Amal Therapeutics SA
c/o Fondation pour Recherches Médicales
64 av. de la Roseraie
Website by Instinctif Partners